BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND
November 26 2019 - 7:05AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the
development of innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today that the
Company is proud to be a gold sponsor of the 30th International
Symposium on ALS/MND.
The symposium will take place December 4 – 6,
2019, at the Perth Convention and Exhibition Centre in Perth,
Australia. The International Symposium on ALS/MND is a unique
annual event that brings together leading international researchers
and health and social care professionals to present and debate key
innovations in their respective fields.
Ralph Kern MD MHSc, BrainStorm’s Chief Operating
and Chief Medical Officer, will deliver a podium presentation:
“Modulation of innate immunity by MSC-NTF (NurOwn®) cells
correlates with ALS clinical outcomes”, on December 4,
from 11:50 – 12:10 pm AWST during the opening day Clinical Trials
Session. In addition to the podium presentation, the Company
will also present Poster 153: “MSC-NTF Differentiation
Increases the Neurotrophic Effects of MSC Cells: Live Imaging
Analysis”, that directly demonstrates the neuroprotective
effects of NurOwn® in a neuronal cell culture model.
“Our fully-enrolled phase 3 clinical trial is
one of the most advanced clinical programs in ALS,” stated Chaim
Lebovits, President and CEO of BrainStorm. He added, “The
International Symposium on ALS/MND is an important venue to update
the community on our clinical and scientific efforts towards the
advancement of therapies that may address the unmet needs of those
living with ALS. BrainStorm Cell Therapeutics is proud to serve as
a sponsor of this important annual symposium which underscores our
commitment to the international community of ALS and MND patients,
their families and their caregivers.”
Ralph Kern, MD, stated, “It is a privilege to
present our innovative biomarker and preclinical research at the
International Symposium on ALS/MND.” He added, “Every year,
symposium participants gather together and discuss the
opportunities and the challenges that we will face during the
upcoming year. Research and medical breakthroughs for the ALS and
MND community continue to make significant progress and we look
forward to sharing our insights and engaging with colleagues from
around the globe. The International Symposium on ALS/MND
reminds us how far we have come in investigational therapies and
how much more progress is still needed to bring patients a better
and more promising future.”
About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm has
fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells
for the treatment of amyotrophic lateral sclerosis (ALS).
BrainStorm also received U.S. FDA acceptance to initiate a Phase 2
open-label multicenter trial in progressive MS and enrollment began
in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
The International Symposium on ALS/MND is a
unique annual event that brings together leading international
researchers and health and social care professionals to present and
debate key innovations in their respective fields. The Symposium is
planned as two parallel meetings, one on biomedical research and
the other on advances in the care and management of people affected
by ALS/MND. Joint sessions consider issues of mutual concern,
challenging current views and practices.
Safe-Harbor
Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may," "should," "would,"
"could," "will," "expect," "likely," "believe," "plan," "estimate,"
"predict," "potential," and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
BRAINSTORM CONTACTS: Investors: Uri Yablonka,
Chief Business Officer BrainStorm Cell Therapeutics Inc Phone: :
+1-201-488-0460 Email: uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone: +1.646.677.1839
Email: sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024